These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

283 related items for PubMed ID: 11304662

  • 1. Cyclooxygenase-2--specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients.
    Whelton A, Fort JG, Puma JA, Normandin D, Bello AE, Verburg KM, SUCCESS VI Study Group.
    Am J Ther; 2001; 8(2):85-95. PubMed ID: 11304662
    [Abstract] [Full Text] [Related]

  • 2. Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis.
    Whelton A, White WB, Bello AE, Puma JA, Fort JG, SUCCESS-VII Investigators.
    Am J Cardiol; 2002 Nov 01; 90(9):959-63. PubMed ID: 12398962
    [Abstract] [Full Text] [Related]

  • 3. A model analysis of costs of blood pressure destabilization and edema associated with rofecoxib and celecoxib among older patients with osteoarthritis and hypertension in a Medicare Choice population.
    Becker RV, Burke TA, McCoy MA, Trotter JP.
    Clin Ther; 2003 Feb 01; 25(2):647-62. PubMed ID: 12749519
    [Abstract] [Full Text] [Related]

  • 4. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
    Sowers JR, White WB, Pitt B, Whelton A, Simon LS, Winer N, Kivitz A, van Ingen H, Brabant T, Fort JG, Celecoxib Rofecoxib Efficacy and Safety in Comorbidities Evaluation Trial (CRESCENT) Investigators.
    Arch Intern Med; 2005 Jan 24; 165(2):161-8. PubMed ID: 15668361
    [Abstract] [Full Text] [Related]

  • 5. The prevalence of cardiorenal risk factors in patients prescribed nonsteroidal anti-inflammatory drugs: data from managed care.
    Harley C, Wagner S.
    Clin Ther; 2003 Jan 24; 25(1):139-49. PubMed ID: 12637116
    [Abstract] [Full Text] [Related]

  • 6. Blood pressure control and rates of edema following the administration of the cyclooxygenase-2 specific inhibitors celecoxib versus rofecoxib in patients with systemic hypertension and osteoarthritis.
    Weaver A, Alderman M, Sperling R.
    Am J Cardiol; 2003 May 15; 91(10):1291-2. PubMed ID: 12745131
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Treating osteoarthritis with cyclooxygenase-2-specific inhibitors: what are the benefits of avoiding blood pressure destabilization?
    Grover SA, Coupal L, Zowall H.
    Hypertension; 2005 Jan 15; 45(1):92-7. PubMed ID: 15545508
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial.
    Geba GP, Weaver AL, Polis AB, Dixon ME, Schnitzer TJ, Vioxx, Acetaminophen, Celecoxib Trial (VACT) Group.
    JAMA; 2002 Jan 02; 287(1):64-71. PubMed ID: 11754710
    [Abstract] [Full Text] [Related]

  • 13. Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet.
    Schwartz JI, Vandormael K, Malice MP, Kalyani RN, Lasseter KC, Holmes GB, Gertz BJ, Gottesdiener KM, Laurenzi M, Redfern KJ, Brune K.
    Clin Pharmacol Ther; 2002 Jul 02; 72(1):50-61. PubMed ID: 12152004
    [Abstract] [Full Text] [Related]

  • 14. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.
    Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC.
    Am J Manag Care; 2002 Oct 02; 8(15 Suppl):S414-27. PubMed ID: 12416791
    [Abstract] [Full Text] [Related]

  • 15. A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database.
    Zhao SZ, Reynolds MW, Lejkowith J, Whelton A, Arellano FM.
    Clin Ther; 2001 Sep 02; 23(9):1478-91. PubMed ID: 11589261
    [Abstract] [Full Text] [Related]

  • 16. A comparison of rofecoxib versus celecoxib in treating pain after dental surgery: a single-center, randomized, double-blind, placebo- and active-comparator-controlled, parallel-group, single-dose study using the dental impaction pain model.
    Malmstrom K, Fricke JR, Kotey P, Kress B, Morrison B.
    Clin Ther; 2002 Oct 02; 24(10):1549-60. PubMed ID: 12462285
    [Abstract] [Full Text] [Related]

  • 17. Blood pressure in Native Americans switched from celecoxib to rofecoxib.
    Fredy J, Diggins DA, Morrill GB.
    Ann Pharmacother; 2005 May 02; 39(5):797-802. PubMed ID: 15797981
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
    Maetzel A, Krahn M, Naglie G.
    Arthritis Rheum; 2003 Jun 15; 49(3):283-92. PubMed ID: 12794781
    [Abstract] [Full Text] [Related]

  • 20. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.
    Hochberg MC.
    Clin Exp Rheumatol; 2001 Jun 15; 19(6 Suppl 25):S15-22. PubMed ID: 11695246
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.